Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor

Abstract

Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg / kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg / kg per day.

Description

TECHNICAL FIELD [0001] The present invention relates to an agent for treating or preventing an inflammatory bowel disease, comprising a particular amino acid(s). The present invention also relates to an agent for inhibiting TNF production, comprising a particular amino acid(s). BACKGROUND ART [0002] An inflammatory bowel disease is a generic term for enteropathy with inflammation, and mainly includes ulcerative colitis and Crohn's disease. The ulcerative colitis is a diffuse non-specific inflammatory disease where large bowel mucosa or submucosa is affected and erosion or ulcer is often formed. Clinical symptoms are mucous and bloody stools, abdominal pain, blood stools, watery stools, fever, lack of appetite, malevolence, emesis and the like. As agents for treating the ulcerative colitis, salazosulfapyridine, adrenal cortex steroids, immunosuppressants, 5-aminosalicylic acid (5-ASA) and the like are used, but it can not be said that these agents are enough to treat the ulcerative c...

AI Technical Summary

Benefits of technology

[0006] As a result of an extensive study on inflammatory bowel diseases and TNF-α production for accomplishing the above objects, the present inventor has found that an excellent effect is obtained by administering a particular amino acid(s) in a particular amount(s), and completed the present invention.

Problems solved by technology

In the high calorie infusion, a risk of bacterial translocation is increased.

However, it can be said that the administration of these agents is insufficient yet for treating the Crohn's disease.

However, they have diverse action points and do not have an inhibitory action specific for TNF-α.

Thus, it is likely to elicit harmful side effects.

Particularly, the side effect of the steroid agent has become a medical problem.

Additionally, the formation of a neutralization antibody has been reported, and thus they can not be said to be sufficient.